The specificity of these isotopes can be further improved via conjugation to molecules specific to receptors on the tumour, such as HER-2 antibody Pertuzumab [45] or prostate specific membrane antigen (PSMA) [46,47]. Here, FOLH1 is linked to neoplasm.